Research & Development

Our Pipeline

Leveraging the REVO-U off-the-shelf CAR-T platform and iTreg technology to deliver transformative therapies across hematologic malignancies, solid tumors, autoimmune diseases, and organ transplantation.

9
Programs
5
Targets Disclosed
4
Therapeutic Areas
2
Platforms

Clinical & Preclinical Pipeline

REVO-U Allogeneic CAR-T
iTreg Platform
Planned
REVO-U Allogeneic CAR-T Platform
Gene-editing-free · Modular design · Scalable manufacturing (>3,000 doses/batch)
Product Target Indication Preclinical IIT Phase I Phase II
UWD-19 LEAD CD19
B-cell Lymphoma / Leukemia Multiple Autoimmune Diseases
UWD-19B DUAL
CD19 + BCMA
Multiple Myeloma Multiple Autoimmune Diseases
UWD-02 Undisclosed
Acute Myeloid Leukemia (AML)
UWD-01 Solid Tumor GUCY2C
Colorectal Cancer Gastric Cancer, Esophageal Cancer
UWD-03 Solid Tumor GPC3
Hepatocellular Carcinoma Lung Squamous Cell Carcinoma
UWD-04 Solid Tumor DLL3
Small Cell Lung Cancer
UWD-05 Solid Tumor Undisclosed
Pancreatic Cancer Ovarian / Lung / Head & Neck Cancer
UWD-06 Solid Tumor Undisclosed
Breast Cancer
iTreg Platform
Induced Regulatory T Cells · Immune Tolerance Engineering
Product Target Indication Preclinical IIT Phase I Phase II
WD-iT1 Transplant —
Kidney Transplantation Liver / Lung Transplantation

REVO-U Platform: Gene-editing-free allogeneic CAR-T with modular architecture enabling multi-target expansion. Scalable manufacturing at >3,000 doses per batch.

iTreg Platform: Clinical data in 2 kidney transplant patients demonstrating reduced immunosuppressant usage. CAR-iTreg development underway with the goal of complete immunosuppressant withdrawal.

All programs are investigational. Pipeline stages reflect current development status and are subject to change.

  • North Area, Building E, Floors 3-4, Qianhai Shenzhen-Hong Kong Youth Innovation Hub, Nanshan District, Shenzhen, Guangdong Province, China
  • 0755-86971801

微信公众号

Copyright © 2024 Wondercel Therapeutics Powered by vancheer